PEBP1 and hepatocellular carcinoma: Accordingly, RKIP levels have been positively associated with improved clinical outcomes in multiple cancers such as breast, prostate, melanoma, glioma, colorectal, lung, pancreatic, hepatocellular carcinoma, gastric, ovarian, liver, kidney, and other solid and hematological malignancies [11,14,15,19,20,21,22,23,24,25].